US FDA accepts Biocon's cancer drug application for review

Biocon and Mylan ’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for patients in the US.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news